APA (7th ed.) Citation

Murase, J. E., Eyerich, K., Chovatiya, R., Hong, H. C., Bangert, C., Strowd, L., . . . Staumont-Sallé, D. Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Murase, Jenny E., et al. Lebrikizumab Improves Head/neck/face Dermatitis and Erythema and Does Not Increase Treatment-emergent Adverse Events of Head/neck/face Erythema in Patients with Moderate-to-severe Atopic Dermatitis. Taylor & Francis Group.

MLA (9th ed.) Citation

Murase, Jenny E., et al. Lebrikizumab Improves Head/neck/face Dermatitis and Erythema and Does Not Increase Treatment-emergent Adverse Events of Head/neck/face Erythema in Patients with Moderate-to-severe Atopic Dermatitis. Taylor & Francis Group.